WO1990014418A1 - Lignees cellulaires de mastocytome murine produisant l'heparine - Google Patents

Lignees cellulaires de mastocytome murine produisant l'heparine Download PDF

Info

Publication number
WO1990014418A1
WO1990014418A1 PCT/US1990/002779 US9002779W WO9014418A1 WO 1990014418 A1 WO1990014418 A1 WO 1990014418A1 US 9002779 W US9002779 W US 9002779W WO 9014418 A1 WO9014418 A1 WO 9014418A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
heparin
gag
composition
antibodies
Prior art date
Application number
PCT/US1990/002779
Other languages
English (en)
Inventor
Jeffrey D. Esko
Ulf Lindahl
Original Assignee
The Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Uab Research Foundation filed Critical The Uab Research Foundation
Publication of WO1990014418A1 publication Critical patent/WO1990014418A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the invention relates to the field of complex polysaccharides and methods to produce them.
  • it concerns stable cell lines useful for producing antiproliferative polysaccharides and methods to obtain them.
  • Glycosaminoglycans are copolymers of alternating hexosamine and aldouronic acid residues which are found in sulfated forms and are synthesized as proteo- glycans. They have collectively been called mucopoly- saccharides, and various common names apply to members of this class, according to the nature of the hexosamine/ aldouronic acid repeating units.
  • the aldouronic acid is D-glucuronic acid
  • the hexosam ⁇ ine is acetylated 2-amino-2-deoxy-D-galactose (N-acetyl galactosamine, GalNAc).
  • chondroitin sulf te B some of the aldouronic acid is L-iduronic acid and the hexosamine is GalNAc.
  • the aldouronic acid is replaced by D-galactose, and the hexosamine is mostly acetylated 2-amino-2-deoxy-D-glucose (N-acetyl glucosa ine, GlcNAc).
  • heparan sulfate In heparan sulfate and heparin, the hexosamine is mostly acetylated and sulfated glucosamine (GlcNH-), and the aldouronic acid is mostly L- iduronic in heparin and mostly D-glucuronic acid in heparan sulfate.
  • GlcNH- acetylated and sulfated glucosamine
  • aldouronic acid is mostly L- iduronic in heparin and mostly D-glucuronic acid in heparan sulfate.
  • heparan sulfate in general has a higher proportion of glucuronic acid than heparin.
  • heparin used as an anticoagulant
  • Conventional heparin has a molecular weight of 5-25 kd and is extracted as a mixture of various chain lengths by conventional procedures. These procedures involve autolysis and extraction of suitable tissues, such as beef or porcine lung, intestine, or liver, and removal of nonpolysaccharide components.
  • the molecular weight of the chains in the extract is significantly lower than the 60-100 kd known to exist in the polysaccharide chains of the heparin proteo- glycan synthesized in the tissue.
  • the GAG moiety is syn ⁇ thesized bound to a protein core at a serine residue through a tetrasaccharide linkage region of the sequence -D-GlcA-Gal-Gal-Xyl-(SER) , which is then elongated at the D-glucuronic residue with alternate additions of GlcNAc and D-glucuronic acid.
  • the polysaccharide side-chains are modified by a series of enzymes which sequentially deacetylate the N-acetyl glucosamine and replace the acetyl group with sulfate, epimerize the hydroxyl at C5 of the D-glucuronic acid residue (to convert it to L-iduronic acid) , sulfate the 0-2 of the resulting L-iduronic acid, and then sulfate the 0-6 of the glucosamine residue.
  • Some of the chains are further sulfated at the 0-3 of the glucosamine residue.
  • 3-0-sulfation can occur in heparan or heparin. This further sulfation is associated with the active site for antithrombin (anticlotting) activity.
  • heparin has a greater content of sulfated glucosamine than heparan and also a higher content of L-iduronic acid. Due to their obvious chemical similarity, iso ⁇ lated "heparin" chains may contain regions of what might otherwise be classified as heparan sulfate.
  • heparin or heparan sulfate preparations from animal tis- sues makes the use of standard animal sources for particular polysaccharide components disadvantageous. It would be far preferable to obtain a clonal source which would permit a dependable and relatively invariant reservoir for these moieties.
  • heparin and heparan sulfate have a variety of bio ⁇ logical activities including activities as anticoagulants, inhibitors of smooth muscle cell proliferation and of antiinflammatory activity in a variety of biological func- tions, depending on the precise composition of the material (see, for example, European Patent Application 287477). Utilization of a clonal source for these materi ⁇ als would permit production of heparin/heparan sulfate with a reproducible spectrum of these activities, as well as providing adequate supplies.
  • Heparin and heparan sulfate can slow or arrest the vascular proliferation associated with injury described hereinabove (Clowes, A. . , et al., Nature (1977) 265;625- 626).
  • the effect of heparan sulfate and heparin on smooth muscle proliferation is also described by Marcum, J.A. , et al., in Biology of Proteoqlycan, Academic Press (1987), pp. 301-343.
  • the inhibition of vascular smooth muscle cell growth by heparin was further described by Castellot, J.J.
  • the present invention provides a reliable and stable source of heparin with antiproliferative activity and a method for obtaining alternate clonal sources of glycosaminoglycans with reproducible spectra of biological activities.
  • the invention is directed to cell lines derived from urine mastocytoma cells. Some cell lines have been selected for their ability to adhere to plastic surfaces. These cell lines secrete a heparin composition which is antiproliferative and relatively lacking in antithrombin- binding activity. The heparin composition is synthesized by these cells despite numerous passages. These and other GAG-producing cells can be screened in tissue culture using a polyester overlay technique to detect clones that produce altered forms of GAG.
  • the cell lines of the invention offer a method to produce, in quantity, polysaccharide compositions which have a variety of bio ⁇ logical activities, including inhibition of smooth muscle cell proliferation.
  • the invention is directed to im- mortal cell lines derived from a suspension of murine mastocytoma cells. These cell lines synthesize a polysaccharide mixture consisting of about 15% chondroitin sulfate and about 85% heparin/heparan sulfate, and the heparin/heparan sulfate fraction of this composition is antiproliferative while having minimal antithrombin- binding activity.
  • the invention is also directed to the heparin/heparan sulfate fraction of this polysaccharide mixture.
  • the invention is directed to immortalized cell lines making the glycosaminoglycan of the above-mentioned composition, which cell lines have been selected for adherence to plastic surfaces.
  • the invention is directed to a method to produce and screen mutant colonies which are defective or effective in GAG synthesis, which comprises inducing colony formation from single adherent cells on tissue culture plates overlaid with one or more disks of poly ⁇ ester cloth so as to result in a transfer of cells from the colonies to the cloth, and then assessing the amount and/or type of GAG synthesized by the transferred cells on the cloth.
  • the invention is directed to pharmaceutical compositions containing the heparin/heparan sulfate compositions exhibiting antiproliferative or other biological activity and to methods to prevent the proliferation of cells or produce other biological effects using these compositions.
  • the invention is directed to antibodies reactive with the antiproliferative heparin/heparan sulfate.
  • Figure 1 shows the elution pattern for the invention heparin on anion-exchange HPLC.
  • heparin/heparan sulfate is meant a prepara ⁇ tion obtained from the cell line and having the characteristics of this mixture, separated from the chondroitin sulfate also produced.
  • This preparation may include residues of D-glucuronic acid (GlcA) as characteristic of heparan sulfate, as well as iduronic acid (IdoA) as characteristic of heparin.
  • GlcA D-glucuronic acid
  • IdoA iduronic acid
  • the conversion of D- glucuronic acid to L-iduronic acid is a result of epimerization at the 5 carbon in a heparan-type inter ⁇ mediate. To the extent that full conversion has not been made, heparan sulfate characteristics remain in the preparation.
  • heparin/heparan sulfate is intended to cover the range of mixtures encountered.
  • the composition of the GAG is reproducible but also contains components which can be considered either heparin or heparan sulfate. Accordingly, this designation is ap ⁇ basementte for such reproducible compositions as well.
  • heparin/heparan sulfate made by the cell lines is stored inside the cells within granules.
  • a crude preparation of cellular heparin/heparan sulfate can be generated by triggering the cells to secrete the mixture with a calcium ionophore or with an IgE antibody and appropriate antigen.
  • the cells can be separated from the growth medium by centrifugation or filtration and treated with alkali, proteases, nucleases, and detergent to remove nonpolysaccharide contaminants.
  • the heparin/heparan sulfate is then collected by anion- exchange chromatography and solvent precipitation. Chondroitin sulfate is removed by digestion with chondroitinase.
  • the cell lines which comprise one aspect of the invention are prepared from suspensions of cells derived from a murine mastocytoma tumor originally described by Furth, J., et al. , Proc Soc Exp Biol (NY) (1957) 95:824- 828. Although this tumor has been serially passaged through mice since its original description and has continuously produced heparin in this in vivo context, previously obtained suspensions of cells derived from the tumor have lost the ability to produce heparin over a period of several months.
  • a suspension of these tumor cells is treated to remove macrophages and fibroblasts according to the procedure of Jacobsson, K.G. , et al., J Biol Chem (1985) 2_60:12154- 12159.
  • the suspension is then treated with streptomycin, penicillin, gentamycin and Fungizone to remove contaminat- ing bacteria and fungi, and the cells are then cultured for three days with tetracycline.
  • Standard growth condi ⁇ tions for the cells are RPMI 1640 growth medium sup ⁇ plemented with 15% heat-inactivated fetal bovine serum and 100 ug/ml of penicillin G at 37°C under an atmosphere of 5% CO- in 95% air.
  • the cells also divide in other types of growth media, performing especially well in formula ⁇ tions of modified Eagle's medium supplemented with as little as 0.5% heat-inactivated fetal bovine serum and 1% bovine serum albumin. Under these conditions the cells divide every 12-15 hours and achieve a density of 1-2 x 10 cell per ml. When this density of cells is achieved, they stop growing, but when diluted with fresh growth medium, they resume exponential growth.
  • the cells can be frozen under liquid nitrogen in growth medium containing 8% glycerol as cryoprotectant and can be recultured in portions when thawed. Preparations of cells derived from a parental line prepared in this manner, and designated MST herein, can be recultured, and they maintain their ability to produce heparin for over six months.
  • cell suspensions derived from a variety of animal mastocytomas, such as human, murine, canine and equine mastocytomas are treated in the manner described above and can be selected for adherence.
  • adherent colonies permits facile assessment of the effects of mutagenesis on the production of glycosaminoglycans and does not itself diminish the capability of the cells to produce GAG compositions with antiproliferative activity.
  • Selection is made by cultur- ing the mastocytoma-derived cell suspensions in plastic cell culture flasks in the culture medium described above, removing unattached cells by replacing the medium every 4 to 7 days, and washing the subset of attached cells to remove loosely adherent cells.
  • a confluent monolayer of firmly attached cells is gener ⁇ ated after 4-6 weeks.
  • the adherent cells are treated with, for example, 0.125% trypsin and 1 mM EDTA to release them as a single cell suspension which can be frozen in liquid nitrogen as described above.
  • MTA Populations of adherent cells prepared from the MST parent suspension described above are designated MTA. These lines also maintain the ability to produce antiproliferative heparin compositions for over three months when passaged in culture.
  • the cell preparations described above can be subcloned into unique clonal cell lines by limiting dilution in microtiter dishes. These cloned cell lines continue to produce heparin with antiproliferative activity.
  • Heparin can be isolated from the cultures of either the mixed suspensions or the cloned cell lines as described above (see Example 2).
  • the heparin preparations from these cells when analyzed by anion-exchange HPLC on TSK-DEAE-3SW, eluted at salt concentrations slightly greater than that required to elute commercial heparin, suggesting a high degree of sulfation.
  • Nitrous acid degradation shows that about 80% of the glucosamine residues are N-sulfated.
  • the nature of the GAG composition can be determined by culturing the cells in the presence of radiolabeled polysaccharide precursors followed by digestion of the resulting radioactive GAGs using chondroitinase ABC. This analysis demonstrates that the cultures or cell lines obtained in this manner contain about 10-25% chondroitin sulfate and about 75-90% heparin.
  • a typical cell line exemplary of the adherent cells prepared by the invention was designated MTA-1 and was deposited at the American Type Culture Collection on and has ATCC No. .
  • This cell line grows continuously in culture and produces heparin/heparan sulfate in a stable manner.
  • the heparin showed antiproliferative activity with respect to cultured smooth muscle cells from blood vessels using an assay described below, and was low in antithrombin-binding activity.
  • the cell line produces about 0.5 ug uronic acid equivalents of heparin per 10 cells; thus, quantities of heparin polysaccharide greater than 100 mg can conveniently be produced.
  • adherent mastocytoma cells as described above facilitates the mutagenesis and screening of mutants which produce desired GAG compositions.
  • adherent cells are treated with mutagens such as methyl methane sulfonate, ethyl methane sulfonate, N-methyl-N'-nitro-N-nitrosoguanidine, or n ⁇ nchemical mutagens such as gamma radiation or ultraviolet light to produce alterations.
  • mutagens such as methyl methane sulfonate, ethyl methane sulfonate, N-methyl-N'-nitro-N-nitrosoguanidine, or n ⁇ nchemical mutagens such as gamma radiation or ultraviolet light to produce alterations.
  • mutagens such as methyl methane sulfonate, ethyl methane sulfonate, N-methyl-N'-nitro-N-nitrosoguanidine, or n ⁇ nchemical mutagens such as
  • the adherent cell lines can also be transfected with DNA that encodes core proteins or enzymes that enable the cells to produce heparin/heparan sulfate.
  • the cells can also be fused with other cell lines that produce un- usual forms of heparin/heparan sulfate that have different biological properties from the forms of heparin/heparan sulfate produced by the mastocytoma cells.
  • These transfected and hybrid cell lines can be replica plated using the polyester overlay technique which enables the identification of specific clones with desired heparin/ heparan sulfate compositions and biological properties.
  • the replica-plating method is described in detail by Esko, J.D., Meth in Cell Biol (1989) 3_2:387-422, incorporated herein by reference.
  • the methods of replica plating of animal cells are considered in general, including assessment of the replicas for heparan sulfate and proteoglycan synthesis in general (Esko, J.D., et al., Proc Natl Acad Sci (USA) (1985) 82_:3197-3201; Esko, J.D., et al. , J Biol Chem (1986) 2_6J.:15725-15733; Esko, J.D., et al.
  • polyester cloth is preferred as an absorbent for cells derived from colonies which are to be assessed for the production of GAGs. Most preferably, a double layer of polyester cloth wherein the lower layer has a larger pore size than the upper layer is used.
  • the cloth layers can be subjected to in situ assays for production of GAGs.
  • the layers are incubated in growth medium containing radioactive sulfate for several hours, then treated with trichloroacetic acid to precipitate radioactive heparin/ heparan sulfate proteoglycans. Unincorporated sulfate is then removed by washing, for example on a Buchner funnel, with additional acid, and the incorporation of the radio ⁇ active sulfate into the precipitated GAGs is assessed by detecting label, for example with X-ray film. Because the cells are adherent, representative colonies remain on the culture plate and can be matched to the results on the absorbing cloth.
  • Another strategy for isolating GAG mutants deficient in sulfating the polysaccharide is based on radiation suicide.
  • a suspension of mutagen-treated cells is incubated with radioactive sulfate, and the labeled cells are stored under liquid nitrogen. Over 4-6 weeks the cells that incorporated radioactive sulfate into heparin/heparan sulfate die due to the decay of the radioactive sulfate.
  • the surviving population of cells is enriched for mutants that are unable to make heparin/heparan sulfate with a high level of sulfation.
  • Individual mutants can be identified and cloned by replica plating as described above.
  • the GAG produced has a low sulfation level, it may have useful biological properties altered from those of the GAG produced in wild type. This screening method has the advantage that it operates by selection.
  • the cloth absorbents can be subjected to extensive analysis for the nature of the GAGs produced and for the quantities obtained. Colonies established on polyester cloth can be tested for antithrombin-binding activity, antiproliferative activity, antiinflammatory activity, growth factor binding activity, and other properties of the GAG produced. These properties can be assessed on a colony-by-colony basis and matched to the growing colonies on the culture plates. For example, colonies on the disks can be gently lysed to release the stored heparin/heparan sulfate.
  • the disks can then be incubated with radioactively labeled antithrombin, and colonies that produce a heparin/heparan sulfate composi- tion that has the antithrombin-binding sequence will bind the radioactive antithrombin. Exposure of the disk to X- ray film permits the detection of clones that produce antithrombin-binding heparin/heparan sulfate.
  • Another technique that can be used to isolate variants that produce more potent antiproliferative heparin/heparan sulfate involves overlaying the colonies on the disks with a thin layer of agar or polyacrylamide. Smooth muscle cells are then placed on top of the agar or acrylamide and permitted to proliferate.
  • mutants are obtained which produce GAGs and heparin/heparan sulfate fractions having the desired biological functions in a reproducible manner.
  • compositions containing predominantly heparin/heparan sulfate separated from the cell cultures herein can be used to stimulate the production of antibod ⁇ ies which immunoreact with the components of the composi ⁇ tion.
  • the composition may be advan ⁇ tageously conjugated to a suitable antigenically neutral carrier, such as an appropriate serum albumin or keyhole limpet hemocyanin, in order to enhance immunogenicit .
  • the antibody-secreting cells of the immunized mammal can be immortalized to generate monoclonal antibody panels which can then be screened for reactivity with the composition
  • ⁇ n vitro immunization procedures can be used to produce human monoclonal antibodies and antibodies to polysaccharide antigens that are weakly immunogenic (Reading, C.L., Meth in Enzymol (1986) 121:18-27; Boss, B.D., Meth in Enzymol (1986) 121:27-33; Borrebaeck, C.A.K., and Moller, S.A., J Immunol (1986) 136:3710-3715. ) Techniques for preparation of mouse monoclonal antibodies to heparin subunits are described by Pejler, G., et al. , J Biol Chem (1988) 263:5197-5201, incorporated herein by reference.
  • the resulting polyclonal or monoclonal antibody preparations are useful in assays for levels of the cor ⁇ responding heparin/heparan sulfate, e.g., the active anti- proliferative component, in biological samples, as described below.
  • the antibodies raised against, e.g., antiproliferative heparin/heparan sulfate compositions can also be used in passive therapy to prevent excessive repression of the proliferation of smooth muscle cells.
  • compositions of the invention containing - predominantly heparin/heparan sulfate are useful in therapeutic applications for treatment of various condi- tions or diseases.
  • compositions which show antiproliferative activity are useful for conditions which are characterized by excessive and destructive smooth muscle cell proliferation. These conditions frequently occur where the subject has been exposed to trauma, such as in the case of surgical patients. The trauma caused by wounds or surgery results in vascular damage, and second ⁇ ary smooth muscle cell proliferation results in vascular retinosis.
  • This undesirable result can occur after vascular graft surgery, heart transplantation, balloon or laser angioplasty, arterial traumatic injury, postsurgical repair of muscular arteries, long-term in-dwelling of arterial catheters, invasive arterial diagnostic procedures, kidney, lung or liver transplants, coronary artery bypass surgery, carotid artery bypass surgery, femoral popliteal bypass surgery, and intracranial arte- rial bypass surgery.
  • Typical dosage ranges are in the range of 0.1- 10 mg/kg/hr on a constant basis over a period of 5-15, preferably 7-10, days. Particularly preferred dosage is about 0.5 mg/kg/hr, or, for a 70 kg adult, 35 mg/hr or 840 mg/day.
  • Formulations suitable for the foregoing modes of administration are known in the art, and a suitable com- pendium of formulations is found in Remington 's
  • the antiproliferative compositions of the inven ⁇ tion may also be labeled using typical methods such as radiolabeling, fluorescent labeling, conjugation with chromophores or enzymes and used in a competitive assay for the amount of antiproliferative component in a bio ⁇ logical sample.
  • Suitable protocols for competitive assays of analytes in biological samples are well known in the art, and generally involve treatment of the sample, in admixture with the labeled competitor, with a specific finding partner which is reactive with analyte such as, typically, an immunoglobulin or fragment thereof.
  • the antibodies prepared according to the invention are useful for this purpose.
  • the binding of analyte and competitor to the antibody can be measured by removing the bound complex and assaying either the complex or the supernatant for label.
  • the separation can be made more facile by preliminary conjugation of the specific binding partner to a solid support.
  • the antibodies of the invention are useful in immunoassays, not only of the type described above involv ⁇ ing competition between labeled composition and the analyte antiproliferation factor in the sample, but also for direct immunoassay for the factor. Alternate proto ⁇ cols involving direct assays are also of wide variety and well known.
  • the analyte bound to antibody is detected by means of an additional reactive partner which bears a label or other means of detection.
  • the binding of the antibodies of the invention to analyte can be detected by further reaction with a labeled preparation of these same antibodies or by labeled antibody immunoreactive with this preparation by virtue of species differences.
  • the antibodies of the invention can also be formulated into pharmaceutical compositions and used to stimulate the growth of smooth muscle cells in subjects for which this result is desirable.
  • Monoclonal antibodies against antiproliferative heparin/heparan sulfate can be used to produce a second generation of antibodies which recognize the binding site for the carbohydrate within the original monoclonal anti- body.
  • These second generation antibodies are called internal image antibodies or antiidiotypic antibodies, and they mimic the structure of the original carbohydrate antigen.
  • Such antibodies should have the properties of the original antigen and thus would be expected to be agonists.
  • the treated cells were cultured for three days with tetra- cycline in RPMI 1640 growth medium supplemented with 15% heat-inactivated fetal bovine serum and then maintained in RPMI 1640 growth medium supplemented with 15% heat- inactivated fetal bovine serum and 100 U/ml of penicillin G.
  • the cells were grown under a 5% C0 2 /95% air mixture at 37°C.
  • the cultured cells were stored frozen under liquid nitrogen in growth medium containing 8% glycerol as cryoprotectant, and were designated MST.
  • Subclones of the MST line were generated by limiting dilution in microtiter dishes yielding eight sublines designated MST1-8.
  • These clones and the parental cell population grow as single cells or aggregates in suspension and divide every 12-16 hr. They grow in a variety of growth media, especially well in various preparations of Eagle's medium and Ham's F10 medium containing as little as 0.5% heat-inactivated fetal bovine serum and 1% bovine serum albumin.
  • the parental MST cells are also capable of forming tumors in athymic (nu/nu) Balb/c mice and Leaden x A strain F.. hybrid mice.
  • Heparin was recovered from the parental MST culture by first separating the cells from the growth medium by centrifugation. The cell pellet was washed once with phosphate-buffered saline and solubilized at room temperature for 15 minutes in 0.1 M sodium hydroxide (25 g ml/10 cells).- The viscous solution was adjusted to pH
  • the column was washed with 100 ml of 0.4 M NaCl/20 mM sodium acetate/0.2% Zwittergent 3-12 (pH 6.0) to remove lipids and other nonpolysaccharide contaminants, and then with 300 ml of 0.4 M NaCl/20 mM sodium acetate to remove residual detergent. Heparin was eluted with 100 ml of 2 M NaCl/20 mM sodium acetate, dialyzed, and lyophilized. The final salt concentration was 0.1 M NaCl/50 mM sodium acetate, and the solution was adjusted to pH 7.0 and 10 mM MgCl 2 .
  • RNA and DNA were digested overnight at room temperature by addition of 10 mg of RNAse A and 1 mg of DNAse I. Chondroitin sulfate was digested by two addi ⁇ tions of 0.5 U of chondroitinase ABC (37°C, 3 hr) . Residual peptides covalently bound to heparin were removed by adjusting the solution to 0.5 N NaOH/1 M NaBH. and incubation at 4 C for 24 hours.
  • the solution was neutralized with acetic acid, diluted with water to 40 ml, and chromatographed on a 5 ml bed of DEAE-Sephacel.
  • Nonheparin contaminants were removed with 100 ml of 0.4 M NaCl/20 mM Sodium acetate (pH 6), and pure heparin was eluted with 25 ml of 2 M NaCl/20 mM sodium acetate.
  • the sample was dialyzed against 0.1 M sodium acetate, lyophilized, dissolved in 5 ml of water, and precipitated with 4 volumes of ethanol.
  • the final preparation was dissolved in phosphate-buffered saline and contained no detectable protein or nucleic acid by UV- light adsorption.
  • the parent MST culture was evaluated for heparin content by the carbazole reaction described by Bitter, T., and Muir, H.M. , Anal Biochem (1962) 4_:330-334.
  • This uncloned parent culture contained 0.5-1.0 ug heparin/10 cells.
  • the degree of variation of production among the subclones was about a factor of 20.
  • the recovered heparin was analyzed on anion exchange HPLC using TSK-DEAE-3SW.
  • the elution profile is shown in Figure 1; the position of the eluted material indicates a high level of sulfation.
  • the isolated heparin was subjected to complete digestion in nitrous acid, and the extent of digestion showed that about 80% of the glucosamine residues are N-sulfated.
  • the relative amounts of heparin/heparan sulfate and chondroitin sulfate produced by clones MST1-8 were determined by digesting radioactive GAGs by chondroitinase ABC, according to the method of Suzuki, S., Meth in Enzymol (1972) 2_ :911-917.
  • the MST cell lines contained about 10-25% chondroitin sulfate and about 75-90% heparin.
  • the MST parent cell culture was also evaluated with respect to ability of the secreted heparin to inhibit the proliferation of bovine aortic smooth muscle cells by a modification of the method of Castellot, J.J., Jr., Seminars in Thrombosis and Hemostatis (1987) 13:489-503, as follows. Solutions to be tested were made up in "complete medium, " which is DMEM medium containing 10% fetal bovine serum and penicillin/streptomycin.
  • Bovine smooth muscle cells were isolated from bovine pulmonary artery by the method of Benitz, W.E., et al., J Cell Physiol (1986) 127:1-7. SMC from passages 3-10 were plated at 350-700 cells per well in 96- well microtiter plates in the medium above and allowed to attach for 2-4 hr. The complete medium was replaced with DMEM supplemented with 0.1% fetal bovine serum, and the cells were incubated for an additional 72 hr to arrest cell growth. The low-serum medium was then replaced with complete medium containing the test samples.
  • LDH lactate dehydrogenase
  • MST parent cell culture heparin inhibited cell growth at l/15th the concentration required by commercial heparin.
  • the heparin secreted by the MST parental line was also tested for ability to bind human antithrombin columns, according to the procedure of Hook, M. , et al. , FEBS Lett (1976) £6:90-93. Less than 1-2% of the total heparin was bound to antithrombin; this suggests that the material may lack anticoagulant activity. This activity is lower than that found in heparin secreted by the mastocytoma tumors from which they originated, which generally contains 15% of high-a finity antithrombin- binding material (Jacobsson, K.-G., et al. , J Biol Chem (1985) 260:12154-12159) . Commercial heparin generally contains about 30% high-affinity material.
  • MTA Adherent
  • the MST parent cell culture was grown in RPMI 1640 medium supplemented with 15% heat-inactivated fetal bovine serum in plastic cell culture flasks. During growth, a few cells attached to the surface; the un ⁇ attached cells were removed from the flask by changing the medium, and the adherent cells continued to proliferate. The medium was changed every 4-7 days, and the monolayer was vigorously washed to remove loosely adherent cells. A confluent monolayer of firmly attached cells was generated after 4-6 weeks.
  • the monolayer was treated with 0.1% trypsin and 1 mM EDTA in order to release the cells as a suspension, and the released suspension, designated MTA, was frozen in liquid nitrogen. Samples of the parent culture were subcloned by limiting dilution to obtain the clonal cell lines MTAl-9.
  • the MTA cell lines were assayed for heparin production using radioactive sulfate incorporation.
  • the radioactive GAGs were about 10- 25% chondroitin sulfate and about 75-90% heparin.
  • the total heparin content of the cloned cell lines was about 0.5 ug/10 cells and varied by a factor of 2 over the lines.
  • the heparin obtained from MTA cell cultures showed chromatographic and antiproliferative properties similar to those obtained in the MST culture.
  • Cells from MTA1 formed tumors in athymic (nu/nu) Balb/c mice.
  • Example 4 Production of Mutants A suspension containing 3 x 10 MTA1 cells was treated with 450 ug/ml of ethyl methane sulfonate. The effectiveness of mutagenesis was assessed by determining the appearance of colonies resistant to ouabain. Stocks having a mutation incidence of more than 10 -4 were used for identification of strains with altered heparin forma ⁇ tion. In order to assess if the amount and type of heparin was altered by the mutagens, mutagenized stocks which showed the required mutation rate were replica plated and assayed for heparin synthesis.
  • a disk of 1-micron pore-diameter cloth was placed on top of the first disk, and a layer of glass beads were added to weight the disks against the bottom of the dish.
  • the cells, sandwiched between the overlay and the bottom of the dish, were incubated at 33°C, and the medium was changed every 5-7 days. After 14 days, colonies that had formed on the plastic dish had also grown through the polyester disks, as shown by staining of a plate and the pair of corresponding disks with Coomassie blue.
  • the medium was aspirated and the beads decanted from the dish.
  • the disks were then removed from the dish with sterile tweezers.
  • the top 1-micron pore-diameter disk was discarded and the lower 27-micron pore-diameter disk was transferred to a bacterial petri dish filled with RPMI 1640 growth medium supplemented with 15% heat-inactivated fetal bovine serum and penicillin G.
  • the replica disks were incubated overnight at 40 C in order to express any temperature- sensitive mutations that might affect heparin synthesis.
  • the disks were transferred to a fresh bacterial petri dish containing 5 ml of RPMI growth medium supplemented with 15% heat-inactivated fetal bovine serum, penicillin G, and 10 uCi/ l of radioactive sulfate.
  • the disks were incubated at 40°C for four hours, removed from the labeled medium, and treated with a few milliliters of 10% trichloroacetic acid to precipitate any radioactive heparin. Unincorporated radioactive sulfate was removed by placing each disk on top of a piece of filter paper in a Buchner funnel and washing the disk with 100 ml of 2% trichloroacetic acid.
  • the disks were dry, they were exposed to X-ray film for 2 days and then they were stained with Coomassie blue. Superimposition of the autoradiograph over the stained disk showed the location of colonies that incorporated less radioactive sulfate than expected from the intensity of the Coomassie blue stain. The low incorporation of radioactive sulfate indicates a deficiency in sulfated GAG synthesis.
  • the dishes were overlaid with a fresh polyester disk moistened with growth medium and refilled with RPMI growth medium supplemented with 15% heat-inactivated fetal bovine serum, 2.5 ug/ml Fungizone, and 100 U/ml penicillin. They were incubated at 33 C for 3 days to allow the colonies to fill in on the plate and then shifted to 28°C, which maintained their viability but prevented them from further growth.
  • the medium in the master dishes was replaced with RPMI 1640 growth medium containing 15% heat-inactivated fetal bovine serum and penicillin G, and they were shifted to 33 C for 3 days.
  • the medium and the overlay were then removed from master dishes that corresponded to the disks which the screening indicated had heparin-deficient clones.
  • the pattern of colonies on the disk and the plate were aligned, and the location of defective colonies was circled on the bottom of the plate.
  • the desired colonies were picked with glass cloning cylinders and localized trypsin/EDTA treatment.
  • the cells were diluted and im ⁇ mediately passed through the screening procedure again in order to confirm the mutant phenotype.
  • a portion of the colony was also cloned by limiting dilution in microtiter plates.
  • Several single-cell clones obtained from the microtiter plates were subjected to the polyester screen ⁇ ing assay to determine which clone was defective. Defec ⁇ tive purified clones were expanded in cell culture and stored under liquid nitrogen. The details of the screen ⁇ ing method and other relevant procedures is given in Esko, J.D., Meth in Cell Biology (1989) 32_:387-422, and refer ⁇ ences therein.
  • Clones deficient in sulfated GAG synthesis are relatively rare, occurring with an incidence of about 10 -4 to 10 " .
  • a portion of mutagen-treated cells were revived from liquid nitrogen and grown to confluence at 33 C.
  • the culture medium was replaced with RPMI 1640 growth medium that had been made without any inorganic sulfate and supplemented with 15% heat-inactivated fetal bovine serum that had been dialyzed against phosphate- buffered saline to remove inorganic sulfate.
  • the culture was shifted to 40°C overnight and then the medium was replaced with the sulfate-free growth medium described above and 30 uCi/ml of radioactive sulfate.
  • the cells were washed with RPMI growth medium containing normal amounts of inorganic sulfate and then harvested with trypsin/EDTA.
  • the cell suspension was concentrated by centrifugation and resuspended in RPMI 1640 growth medium containing 15% heat-inactivated fetal bovine serum and 8% glycerol.
  • the cells were stored frozen under liquid nitrogen in sealed glass ampules at 2 x 10 cells/ml. After 6 weeks, they were thawed, centrifuged to remove the glycerol, and grown for several days at 33°C in normal growth medium. The surviving cells were then passed through the replica-plating screening procedure described in Example 4.
  • the incidence of sulfated GAG-deficient mutants was found to be 10 to 10 2 , or about 3-4 orders of magnitude more frequent than in the original mutagen-treated population prior to enrichment.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des lignées cellulaires qui peuvent être développées en continu en culture et qui donnent des compositions de glycosaminoglycane (GAG) ayant une forte activité antiproliférative par rapport aux cellules de muscles souples. Ces lignées cellulaires permettent la production de grandes quantités de GAGs antiprolifératifs qui n'ont pas d'activité de liaison de l'antithrombine. De plus, l'invention concerne des procédés permettant d'obtenir des lignées cellulaires mutantes qui produisent des compositions GAG avec des spectres d'activité désirés.
PCT/US1990/002779 1989-05-19 1990-05-18 Lignees cellulaires de mastocytome murine produisant l'heparine WO1990014418A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35440789A 1989-05-19 1989-05-19
US354,407 1989-05-19
US39822689A 1989-08-24 1989-08-24
US398,226 1989-08-24

Publications (1)

Publication Number Publication Date
WO1990014418A1 true WO1990014418A1 (fr) 1990-11-29

Family

ID=26998387

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/002779 WO1990014418A1 (fr) 1989-05-19 1990-05-18 Lignees cellulaires de mastocytome murine produisant l'heparine

Country Status (2)

Country Link
AU (1) AU5810690A (fr)
WO (1) WO1990014418A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
FR2831186A1 (fr) * 2001-10-22 2003-04-25 Aventis Pharma Sa Production d'heparine a partir de cultures de mastocytes
FR2853663A1 (fr) * 2003-04-14 2004-10-15 Aventis Pharma Sa Procede d'obtention de lignees de mastocytes a partir de tissus de porcs et procede de production de molecules de type heparine
FR2876386A1 (fr) * 2004-10-12 2006-04-14 Aventis Pharma Sa Lignees de mastocytes porcins produisant des molecules de type heparine
WO2017106782A1 (fr) * 2015-12-18 2017-06-22 Tega Therapeutics, Inc. Compositions de glycosaminoglycane cellulaire et leurs procédés de préparation et d'utilisation
WO2018112434A1 (fr) * 2016-12-16 2018-06-21 Tega Therapeutics, Inc. Compositions in vitro d'héparine et de sulfate d'héparane et leurs procédés de fabrication et d'utilisation
WO2021041711A1 (fr) * 2019-08-27 2021-03-04 Tega Therapeutics, Inc. Héparine et sulfate d'héparane issus de cellules mst modifiées et procédés de fabrication et d'utilisation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4824436A (en) * 1985-04-09 1989-04-25 Harvey Wolinsky Method for the prevention of restenosis
US4840940A (en) * 1987-10-21 1989-06-20 Sottiurai Vikrom S Method for reducing the occurrence of distal anastomotic intimal hyperplasia using fractionated heparin
US4849339A (en) * 1984-06-08 1989-07-18 Rockefeller University Method for determination and diagnosis of non-goodposture glomerulonephritis
US4883751A (en) * 1986-05-28 1989-11-28 New York University Specific immunoassay for heparin

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849339A (en) * 1984-06-08 1989-07-18 Rockefeller University Method for determination and diagnosis of non-goodposture glomerulonephritis
US4824436A (en) * 1985-04-09 1989-04-25 Harvey Wolinsky Method for the prevention of restenosis
US4883751A (en) * 1986-05-28 1989-11-28 New York University Specific immunoassay for heparin
US4840940A (en) * 1987-10-21 1989-06-20 Sottiurai Vikrom S Method for reducing the occurrence of distal anastomotic intimal hyperplasia using fractionated heparin

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CIRCULATION RESEARCH, Volume 46, Number 5, pages 625-634, May 1980, "Inhibition of rat arterial smooth muscle cell proliferation by heparin", (See entire document). *
FEBS LETTERS, Volume 66, Number 1, pages 90-93, July 1976, "Anticoagulant activity of heparin: Separation of high-activity and low-activity heparin species by affinity chromatography on immobilized antithrombin", HOOK et al.: (See entire document). *
NEUROSURGERY, Volume 25, Number 6, pages 892-898, December 1989: "Localized release of perivascular heparin inhibits intimal proliferation after endothelial injury without systemic anticoagulation", OKADA et al., (See title, introduction, figures 1 and 3). *
PROCEEDINGS NATIONAL ACADEMY OF SCIENCES (USA), Volume 82, pages 3197-3201, May 1985, "Animal cell mutanis defective in glycosaminoglycan biosynthesis", ESKO et al., (See entire document). *
THE BIOCHEMICAL JOURNAL, Volume 246, Number 2, pages 409-415, 01 September 1987, "Degradation of heparin proteoglycan in cultured mouse mastocytoma cells", JACOBSSON et al.: (See page 410, bridge paragraph of left and right columns; figure 4, legend). *
THE JOURNAL OF CELL BIOLOGY, Volume 107, Number 6, part 3, page 157a, Abstract Number 892, December 1988, "Replica plating of murine mastocytoma cells", MONTGOMERY et al.: (See entire abstract). *
TRANSPLANTATION PROCEEDINGS, Volume 21, Number 4, pages 3700-3701, August 1989, "Inhibition of smooth muscle cell proliferation by heparin molecules", CLOWES et al.: (See page 3700, 2nd paragraph). *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
FR2831186A1 (fr) * 2001-10-22 2003-04-25 Aventis Pharma Sa Production d'heparine a partir de cultures de mastocytes
WO2003035886A2 (fr) * 2001-10-22 2003-05-01 Aventis Pharma S.A. Preparation d'heparine a partir de cultures de mastocytes
WO2003035886A3 (fr) * 2001-10-22 2004-02-26 Aventis Pharma Sa Preparation d'heparine a partir de cultures de mastocytes
FR2853663A1 (fr) * 2003-04-14 2004-10-15 Aventis Pharma Sa Procede d'obtention de lignees de mastocytes a partir de tissus de porcs et procede de production de molecules de type heparine
WO2004092356A2 (fr) * 2003-04-14 2004-10-28 Aventis Pharma S.A. Procede d'obtention de lignees de mastocytes a partir de tissus de porcs et procede de production de molecules de type heparine
WO2004092356A3 (fr) * 2003-04-14 2005-05-26 Aventis Pharma Sa Procede d'obtention de lignees de mastocytes a partir de tissus de porcs et procede de production de molecules de type heparine
FR2876386A1 (fr) * 2004-10-12 2006-04-14 Aventis Pharma Sa Lignees de mastocytes porcins produisant des molecules de type heparine
WO2006040463A1 (fr) * 2004-10-12 2006-04-20 Aventis Pharma S.A. Lignees de mastocytes porcins produisant des molecules de type heparine
WO2017106782A1 (fr) * 2015-12-18 2017-06-22 Tega Therapeutics, Inc. Compositions de glycosaminoglycane cellulaire et leurs procédés de préparation et d'utilisation
EP3389674A4 (fr) * 2015-12-18 2019-09-11 Tega Therapeutics, Inc. Compositions de glycosaminoglycane cellulaire et leurs procédés de préparation et d'utilisation
AU2016369595B2 (en) * 2015-12-18 2022-11-24 Tega Therapeutics, Inc. Cellular glycosaminoglycan compositions and methods of making and using
US11549000B2 (en) 2015-12-18 2023-01-10 Tega Therapeutics, Inc. Cellular glycosaminoglycan compositions and methods of making and using
WO2018112434A1 (fr) * 2016-12-16 2018-06-21 Tega Therapeutics, Inc. Compositions in vitro d'héparine et de sulfate d'héparane et leurs procédés de fabrication et d'utilisation
WO2021041711A1 (fr) * 2019-08-27 2021-03-04 Tega Therapeutics, Inc. Héparine et sulfate d'héparane issus de cellules mst modifiées et procédés de fabrication et d'utilisation

Also Published As

Publication number Publication date
AU5810690A (en) 1990-12-18

Similar Documents

Publication Publication Date Title
US5032679A (en) Heparin fragments as inhibitors of smooth muscle cell proliferation
Thompson et al. Proteoglycan and glycosaminoglycan synthesis in embryonic mouse salivary glands: effects of beta-D-xyloside, an inhibitor of branching morphogenesis.
EP0341006B1 (fr) Inhibiteur de la croissance des cellules des muscles lisses
EP1870421B1 (fr) Anticorps de sulfate d'anti-héparane, procédé pour la détection du sulfate d'héparane, et nécessaire pour la détection du sulfate d'héparane
WO1992017188A1 (fr) Nouveaux derives de l'heparine non anticoagulants
Conrad et al. Heparan sulfate biosynthesis by embryonic tissues and primary fibroblast populations
Nibbering et al. Quantitative immunocytochemical characterization of mononuclear phagocytes. II. Monocytes and tissue macrophages.
Eugene et al. Absence of normal keratan sulfate in the blood of patients with macular corneal dystrophy
AU637046B2 (en) Biologically active material characterised by catabolic activity generally associated with cachexia-inducing tumours, preparations, production and uses thereof
Singal et al. Absence of Detectable HL—A Antigens on Cultured Fibroblasts in Progeria
Yaoita et al. Isolation and characterization of proteoglycans synthesized by cultured mesangial cells.
WO1990014418A1 (fr) Lignees cellulaires de mastocytome murine produisant l'heparine
EP0669827B1 (fr) Compositions utilisees dans la regulation de l'activite de la cytokine
McEuen et al. Mass, charge, and subcellular localization of a unique secretory product identified by the basophil-specific antibody BB1
Allard et al. Chondrocyte-derived cells and matrix at the rheumatoid cartilage-pannus junction identified with monoclonal antibodies
Lowe-Krentz et al. Multiple heparan sulfate proteoglycans synthesized by a basement membrane-producing murine embryonal carcinoma cell line
US6750207B1 (en) Compositions for the regulation of cytokine activity
Kraemer Production of heparin related glycosaminoglycans by an established mammalian cell line
US7491708B1 (en) Modified pectin
Pacifici et al. 12-O-tetradecanoylphorbol-13-acetate-induced changes in sulfated proteoglycan synthesis in cultured chondroblasts
Van Lent et al. Allergic arthritis induced by cationic antigens: relationship of chronicity with antigen retention and T-cell reactivity.
Bhavanandan Glycosaminoglycans of cultured human fetal uveal melanocytes and comparison with those produced by cultured human melanoma cells
Olds et al. Differential immunoregulation of granulomatous inflammation, portal hypertension, and hepatic fibrosis in murine schistosomiasis mansoni.
Garin et al. Effect of lymphokine from nephrotic peripheral blood mononuclear cells on catabolism of rat glomerular basement membrane sulfated compounds
Palmoski et al. Stimulation of glycosaminoglycan biosynthesis by amyloid fibrils.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR JP NO

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE